[{"id":"ccf05c14-1b2b-4e33-86b3-d96e611fe35e","acronym":"TACTIVE-U Sub-Study B","url":"https://clinicaltrials.gov/study/NCT05573555","created_at":"2022-10-10T14:05:34.283Z","updated_at":"2025-02-25T15:27:42.066Z","phase":"Phase 1/2","brief_title":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)","source_id_and_acronym":"NCT05573555 - TACTIVE-U Sub-Study B","lead_sponsor":"Pfizer","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • vepdegestrant (ARV-471)"],"overall_status":"Recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-02-11"},{"id":"e26f4832-18d8-4dd8-a4b0-bfc0f47b73b1","acronym":"VERITAC","url":"https://clinicaltrials.gov/study/NCT04072952","created_at":"2021-01-18T19:56:21.491Z","updated_at":"2025-02-25T15:26:10.187Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Trial of ARV-471 Alone and in Combination with Palbociclib (IBRANCE®) in Patients with ER+/HER2- Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT04072952 - VERITAC","lead_sponsor":"Arvinas Estrogen Receptor, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • vepdegestrant (ARV-471)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 217","initiation":"Initiation: 08/05/2019","start_date":" 08/05/2019","primary_txt":" Primary completion: 09/13/2024","primary_completion_date":" 09/13/2024","study_txt":" Completion: 03/13/2025","study_completion_date":" 03/13/2025","last_update_posted":"2025-02-11"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"3664f3ff-fa68-4517-8986-00649bcc87de","acronym":"VERITAC-3","url":"https://clinicaltrials.gov/study/NCT05909397","created_at":"2023-06-18T17:07:52.437Z","updated_at":"2024-07-02T16:34:37.580Z","phase":"Phase 3","brief_title":"A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer","source_id_and_acronym":"NCT05909397 - VERITAC-3","lead_sponsor":"Pfizer","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole • vepdegestrant (ARV-471)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1180","initiation":"Initiation: 08/09/2023","start_date":" 08/09/2023","primary_txt":" Primary completion: 08/28/2028","primary_completion_date":" 08/28/2028","study_txt":" Completion: 07/26/2030","study_completion_date":" 07/26/2030","last_update_posted":"2024-06-06"},{"id":"c370e70c-4374-44ba-9cc4-3775e27b9fe9","acronym":"C4891006","url":"https://clinicaltrials.gov/study/NCT05548127","created_at":"2022-09-21T18:56:15.546Z","updated_at":"2024-07-02T16:34:37.755Z","phase":"Phase 1/2","brief_title":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)","source_id_and_acronym":"NCT05548127 - C4891006","lead_sponsor":"Pfizer","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • vepdegestrant (ARV-471)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/23/2023","start_date":" 02/23/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-06"},{"id":"713d326d-ce49-4a82-8f3e-93bb3f6bd52e","acronym":"TACTIVE-N","url":"https://clinicaltrials.gov/study/NCT05549505","created_at":"2022-09-22T15:56:26.835Z","updated_at":"2024-07-02T16:35:05.520Z","phase":"Phase 2","brief_title":"A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery","source_id_and_acronym":"NCT05549505 - TACTIVE-N","lead_sponsor":"Arvinas Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • vepdegestrant (ARV-471)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 02/15/2023","start_date":" 02/15/2023","primary_txt":" Primary completion: 07/15/2024","primary_completion_date":" 07/15/2024","study_txt":" Completion: 08/15/2024","study_completion_date":" 08/15/2024","last_update_posted":"2024-05-07"},{"id":"fd2b53a9-779f-456a-8db0-be845df467ce","acronym":"VERITAC-2","url":"https://clinicaltrials.gov/study/NCT05654623","created_at":"2022-12-16T14:58:25.308Z","updated_at":"2024-07-02T16:35:07.584Z","phase":"Phase 3","brief_title":"A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.","source_id_and_acronym":"NCT05654623 - VERITAC-2","lead_sponsor":"Pfizer","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • vepdegestrant (ARV-471)"],"overall_status":"Recruiting","enrollment":" Enrollment 560","initiation":"Initiation: 03/03/2023","start_date":" 03/03/2023","primary_txt":" Primary completion: 08/14/2024","primary_completion_date":" 08/14/2024","study_txt":" Completion: 05/15/2028","study_completion_date":" 05/15/2028","last_update_posted":"2024-04-25"},{"id":"7dd3fe67-f0b4-44c1-9763-8377d759d081","acronym":"","url":"https://clinicaltrials.gov/study/NCT05732428","created_at":"2023-02-17T15:00:45.655Z","updated_at":"2024-07-02T16:35:08.668Z","phase":"Phase 1","brief_title":"A Study to Learn About the Study Medicine (Called ARV-471) in People With ER+/HER2- Advanced BC in China","source_id_and_acronym":"NCT05732428","lead_sponsor":"Pfizer","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vepdegestrant (ARV-471)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 02/20/2023","start_date":" 02/20/2023","primary_txt":" Primary completion: 03/29/2024","primary_completion_date":" 03/29/2024","study_txt":" Completion: 11/07/2024","study_completion_date":" 11/07/2024","last_update_posted":"2024-04-19"},{"id":"3bc320df-deac-49ba-b439-513c0371f536","acronym":"TACTIVE-E","url":"https://clinicaltrials.gov/study/NCT05501769","created_at":"2022-08-15T12:10:48.499Z","updated_at":"2024-07-02T16:35:22.732Z","phase":"Phase 1","brief_title":"ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer","source_id_and_acronym":"NCT05501769 - TACTIVE-E","lead_sponsor":"Arvinas Estrogen Receptor, Inc.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • vepdegestrant (ARV-471)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 09/08/2022","start_date":" 09/08/2022","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-01-22"},{"id":"0dbf5909-6829-41da-897d-df2beb19b3c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05463952","created_at":"2022-07-19T15:55:15.864Z","updated_at":"2024-07-02T16:35:36.744Z","phase":"Phase 1","brief_title":"A Study to Learn About the ARV-471 (PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)","source_id_and_acronym":"NCT05463952","lead_sponsor":"Pfizer","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vepdegestrant (ARV-471)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 08/16/2022","start_date":" 08/16/2022","primary_txt":" Primary completion: 05/04/2023","primary_completion_date":" 05/04/2023","study_txt":" Completion: 03/31/2024","study_completion_date":" 03/31/2024","last_update_posted":"2023-09-18"}]